Blood Biomarker Panel for AD/MCI

About Gryphon Bio

Gryphon Bio is a San Francisco-based biotech founded in 2019, pioneering diagnostic-powered therapeutics for brain health. The company's core technology is based on the discovery of thousands of brain-derived molecules in the blood, which fluctuate like waves and provide a novel window into brain conditions. Its initial focus is on developing blood-based biomarker panels for traumatic brain injury (TBI) and Alzheimer's disease (AD), aiming to aid in early detection, monitoring, and therapeutic development. Gryphon is backed by over $13 million in non-dilutive grant funding and is engaging in clinical studies with various partners to validate its tests.

Therapeutic Areas